FDA approves first factor XIa inhibitor after stroke; smartwatch AI flags weak pumping; GLP-1 drugs get optic neuropathy warning

A weekly pill organizer with seven compartments in a row and plain lids, three lids flipped open to show pills.

The Food and Drug Administration (FDA) on Nov. 9 approved asundexian, the first factor XIa inhibitor, for use with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

An AI model read smartwatch ECGs for weak heart pumping in a preliminary study, FDA added a rare optic neuropathy warning to all GLP-1 receptor agonists and team-based care with single-pill combinations lowered blood pressure in a JAMA trial.

  • FDA Nov 9, 2026
    The Food and Drug Administration (FDA) on Nov. 9 approved Bayer's Sunharbo (asundexian) 50 mg, the first factor XIa inhibitor, for use with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. In the phase 3 OCEANIC-STROKE trial of 12,327 adults, it reduced ischemic stroke 26% versus placebo over a median 14.2 months, according to FDA. Overall major bleeding was similar, but it was increased in patients older than 75 and in the first 90 days, and gastrointestinal bleeding was more common. It is not approved for stroke prevention in atrial fibrillation.
    Source: FDA
  • AI Nov 9, 2026
    An AI model analyzed 30-second single-lead smartwatch ECGs to detect left ventricular systolic dysfunction in 2,211 adults referred for echocardiography at one hospital in South Korea, according to an abstract presented Nov. 9 at the American Heart Association (AHA) Scientific Sessions. AHA said the model distinguished people with and without the condition about equally well on Apple Watch and Samsung Galaxy Watch recordings but gave no accuracy figures. In an exploratory analysis of adults recording at home, 81% with consistently positive results had the condition confirmed by echocardiography; the study did not test whether the results lead to earlier treatment.
  • FDA Nov 9, 2026
    The Food and Drug Administration (FDA) on Nov. 9 required all GLP-1 receptor agonist labels to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions. In FDA Sentinel data the hazard ratio was 1.43 (95% CI 1.02 to 2.01) versus DPP-4 inhibitors and 1.19 (95% CI 0.91 to 1.54), not significant, versus SGLT2 inhibitors; trial incidence was 6.4 versus 3.8 events per 100,000 person-years. FDA advises considering discontinuation in patients who develop NAION.
  • Research Nov 8, 2026
    In the CATCH cluster randomized trial of adults with uncontrolled hypertension in Colombia and Jamaica, published Nov. 8 in JAMA and presented at the American Heart Association Scientific Sessions, team-based care built on single-pill combination therapy lowered systolic pressure 19.1 mm Hg versus 9.0 mm Hg with standard care at 18 months (difference 10.1 mm Hg, 95% CI 6.9 to 13.3; P < .001). Pressure below 130/80 mm Hg was reached by 69.5% versus 29.2%, and serious adverse events occurred in 7.9% of the intervention group and 9.9% of the standard care group.
  • Research Nov 10, 2026
    Among 218,234 pregnant patients with respiratory tract infection in MarketScan and Medicaid claims, doxycycline was associated with more pregnancy loss than amoxicillin (adjusted relative risk 1.54, 95% CI 1.41 to 1.68, and 1.40, 95% CI 1.28 to 1.53) and macrolides, according to an active-comparator cohort study published Nov. 10 in Annals of Internal Medicine. For acne, the comparison with topical clindamycin was significant in MarketScan but not Medicaid (1.03, 95% CI 0.80 to 1.33). Risk differences in significant cohorts ranged from 7 to 11 percentage points.

The weekly innovation roundup for internal medicine, published every Sunday for the week before; every item links to its sources. Latest internal medicine news · All specialties

Latest news

Tagged internal medicine, from the daily briefing

  1. Measles deaths reach 10 this year as Pennsylvania and Wisconsin report two more, while the CDC lists six
  2. Lower-dose CagriSema cut body weight 21% versus 2% on placebo at 68 weeks in a 309-patient trial
  3. The U.S. no longer counts as measles-free after 26 years, a regional commission found, news outlets report

See all the latest news